Reata (RETA): Price-to-Revenue Ratio

Brandmark of Reata (RETA)

Integration into a major biotech firm amid a neutral geopolitical backdrop guarantees business stability for Reata Pharmaceuticals (RETA). The price/sales multiple reflects valuation dynamics, with the value fixed at 233.60. Fundamentals rely on the commercial success of Skyclarys and coverage of the orphan segment. Biogen solidified its status as a savior by releasing the first treatment for Friedreich's ataxia, earning the trust of patient communities.

RETA Reata Pharmaceuticals P/S Multiple (07/04/2022 - 10/07/2023)

Metric breakdowns and analytics for Reata (RETA)

- current quotes and average value forecast:
Market Price reatapharma.com|RETA - Price Target Chart
- stock exchange capitalization data:
Market Value Reata|RETA - Total Company Value
- issuer book value statistics:
Net Asset Value per Share Reata Pharmaceuticals|RETA - Book Capitalization|Market Value to Equity Ratio reatapharma.com|RETA - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Reata Pharmaceuticals|RETA - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Reata Pharma|RETA - Company Aggregate Debts|Debts to Book Value Reata|RETA - Company Long-Term Debts|Company Short-Term Debts Reata Pharmaceuticals|Intermediate Liquidity Ratio reatapharma.com
- earnings and multiples data:
RETA - Net Profit|Projected Future Earnings Reata Pharmaceuticals|RETA - Price to Earnings Ratio|Future Price to Earnings Multiple Reata Pharmaceuticals Inc|RETA - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Reata|RETA - Operating profit EBITDA|Earnings per share for the trailing year Reata Pharmaceuticals|RETA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth reatapharma.com|RETA - Earnings per share growth in current year|Expected earnings per share trend next year Reata Pharmaceuticals
- issuer revenue and sales details:
RETA - Company Revenue|Company Future Sales Volume reatapharma.com|RETA - P/S Multiple|Forward P/S Multiple Reata
General company analysis:RETA - reatapharma.com
Mass-produced product of Reata Pharma

The P/S ratio determines the market value of one dollar of revenue, allowing for an assessment of an asset's overvaluation relative to its ability to generate cash flow. Analyzing the price-to-sales ratio for Reata Pharmaceuticals (RETA) is critical, as a high valuation reflects market expectations for breakthrough drugs treating rare pathologies and the effectiveness of large-scale R&D investments.

Competing companies

JAZZ - Price to Sales|Price-to-Revenue Ratio Cytokinetics, Incorporated CYTK|PTC Therapeutics Inc - Price-to-Revenue Ratio|SRRK - Price-to-Revenue Ratio|Price to Sales Centessa Corp|DYN: P/S Multiple|Price-to-Revenue Multiple edgewisetx.com EWTX|Market Cap to Revenue RAPP|Price to Sales Alumis Inc ALMS|Price-to-Revenue Ratio Kempharm (ZVRA)|CTNM (Contineum Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple LRMR (Larimar Therapeutics)|Capricor Therapeutics Inc. (CAPR) - Price to Sales|Entrada Therapeutics, Inc. - P/S Multiple|PTHS - P/S Multiple|MNOV (medicinova.com) - Market Cap to Revenue|SER: Market Cap to Sales Volume|BTAI (BioXcel Therapeutics) - P/S Multiple|P/S Multiple ProMIS|Market Cap to Revenue APUS (Apimeds Pharmaceuticals)|AEON (aeonbiopharma.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio NLS Pharmaceutics NLSP|BNOX (Bionomics Ltd.) - Price-to-Sales Ratio|FSD Pharma - P/S Multiple